BridgeBio Pharma ROA - Return on Assets 2018-2024 | BBIO

BridgeBio Pharma return on assets for the quarter ending September 30, 2024 was -61.39.

  • BridgeBio Pharma average return on assets for 2023 was -91.09, a 49.25% decline from 2022.
  • BridgeBio Pharma average return on assets for 2022 was -61.03, a 6.73% increase from 2021.
  • BridgeBio Pharma average return on assets for 2021 was -57.18, a 16.29% increase from 2020.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.

BridgeBio Pharma ROA - Return on Assets 2018-2024 | BBIO

  • BridgeBio Pharma average return on assets for 2023 was -91.09, a 49.25% decline from 2022.
  • BridgeBio Pharma average return on assets for 2022 was -61.03, a 6.73% increase from 2021.
  • BridgeBio Pharma average return on assets for 2021 was -57.18, a 16.29% increase from 2020.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$24.9B
Dr Reddy's Laboratories (RDY)$12.6B
Bausch Health Cos (BHC)$2.8B
Supernus Pharmaceuticals (SUPN)$2.1B
Amphastar Pharmaceuticals (AMPH)$1.7B
Personalis (PSNL)$396M
Taysha Gene Therapies (TSHA)$314M
Assembly Biosciences (ASMB)$95M
Sol-Gel Technologies (SLGL)$25M
Evoke Pharma (EVOK)$6M
Teligent (TLGT)$0M